Valganciclovir to Reduce T Cell Activation in HIV Infection
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with valganciclovir decreases T
cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV)
co-infection, potentially improving immune responses to antiretroviral therapy.